Drugs / HLX02
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04670796 | Mar → Jun 2021 | — | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 1 | NCT02581748 | Sep 2015 → May 2016 | — | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03084237 | Nov 2016 → Nov 2018 | breast cancer | Shanghai Henlius Biotech | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04670796 ↗ |
| Route | Intravenous | “intravenous infusion over 90 min” PMID 33169186 ↗ Nov 2020 |